Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 15, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction event rather than general financial performance.
Material Changes
The material change reported is an increase in the notional allocation of GSK Ordinary Share ADRs within the US Retirement Savings Plan. This adjustment resulted from a re-valuation of the cash element of the notional investment held in the plan.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or general management commentary. It details a transaction notified on May 15, 2006, concerning an allocation increase on May 11, 2006, at a price of $56.99 per share. The transaction involved the following individuals:
- Dr JP Garnier: 39 shares
- Dr T Yamada: 16 shares
- Dr F Calhoun: 9 shares
- Dr R Greig: 54 shares
- Mr D Phelan: 136 shares
- Dr D Pulman: 10 shares
- Mr D Stout: 23 shares
- Mr C Viehbacher: 3 shares
Investor Verification Points
- Verify the impact of the US Retirement Savings Plan re-valuation on executive compensation structures.
- Confirm the share price of $56.99 per ADR as of May 11, 2006, against market data.
- Review the total notional holdings of the named directors to assess concentration risk.